Credits: Canva
As per the latest data released by Transforming Access to Student Outcomes in Higher Education (TASO) and the Policy Institute at King's College London, the number of UK students reporting mental health difficulties tripled. The estimate reveals that around 300,000 students could now be experiencing mental health struggles. Of the total, 18% of students reported some kind of mental health issue in 2024.
As per the reports, this estimate is triple what was reported in 2017, where it was at 6%. Experts also say that Covid-19 pandemic is "often considered to have contributed to this, it does not explain the ongoing rise in mental health difficulties." Another reason could also be the "changing definition and increasing openness about mental health" which has led to a rise in numbers. The report notes, "This trend pre-dates the Covid-19 pandemic and the cost-of-living crisis. Although these factors play a part in students' deteriorating mental health, they cannot therefore be the only explanation."
The report drew data collected over the latest Student Academic Experience Survey of 93,212 students. From the survey, it was found that there exist significant disparities between demographic groups, with women being twice as likely to report mental health difficulties, about 22% as compared to men, at 11%.
The results revealed that students who identified as LGBTQ experienced the highest rates of mental health challenges. This has actually lessened the hope that conditions for LGBTQ students are improving, which may not have been a positive case.
Of them, 42% are bisexual and lesbian students, whereas last year it was 35% and 32% respectively. The report also noted that mental health difficulties among lesbian women and gay men rose three times the rate of straight people, and among bisexual and asexual people, it was twice as high. For trans students, the number jumped from 25% in 2023 to 40% in 2024.
As per the Child Mind Institute, being LGBTQ+ does not cause mental health problems, but because these kids often face factors like rejection, discrimination and violence, they are at a higher risk of challenges including depression, anxiety, and even attempting suicide.
A UTAH Health study quotes Anna Docherty, PhD, LP, assistant professor of psychiatry at Huntsman Mental Health Institute that, "likely with any identity, feeling different - or worse, unaccepted as you are is a significant risk factor of mental health struggle." The data reveals that LGBTQ+ teens are six times more likely to experience symptoms of depression than non-LGBTQ+ identifying teens. They are also more than twice as likely to feel suicidal and more than four times as likely to attempt suicide. In the US alone, 48% of transgender adults report that they have considered suicide in the last year, compared to 4% of the overall population.
TASO's academic lead and professor of public policy at King's College London, Michael Sanders said, "LGBTQ students and women bear the brunt of the rise in declining mental health and urgent action is needed to understand and address these trends."
Credit: iStock
At least 17 US states have reported cases of watery diarrhea, nausea and fatigue caused by the parasite Cyclospora cayetanensis.
According to the US Centers for Disease Control and Prevention (CDC), 145 people aged between five and 86 contracted the parasite between May 1 and June 16.
Twenty of those infected have been hospitalized. The infections have been reported across 17 states, with the highest number of cases recorded in New York.
"Local, state and federal (CDC, FDA) public health authorities are investigating several clusters of cases in more than one state. Investigations to identify potential sources are ongoing," the CDC said in its update on the outbreak.
New York has reported the highest number of cases, with between 31 and 80 infections, according to The Independent. Illinois and Texas have each reported between 11 and 30 cases. Other affected states include:
Also read: Ebola Scare In UK: Suspected Patient At Glasgow Hospital Tests Negative
Cyclospora infections usually increase during the summer months, and the CDC considers May 1 through August 31 to be the peak cyclosporiasis season. No deaths have been reported in the current outbreak.
As of June 16, the CDC had also recorded 45 travel-related cases of cyclosporiasis among people who became ill after consuming contaminated food or water outside the United States.
Three of those patients were hospitalized, but no deaths have been reported.
Health officials believe the current outbreak is linked to contaminated food consumed within the United States. Most of the affected patients had not travelled outside the country before becoming ill.
The officials are still working to identify the specific food item responsible for the outbreak.
Cyclospora cayetanensis is a parasite that leads to the illness Cyclosporiasis -- a form of food poisoning.
One can get a Cyclospora infection from contaminated food or water. It causes watery diarrhea and other intestinal symptoms.
A Cyclospora infection can be mild or very serious, and may last weeks or months. It is typically treated with antibiotics.
People with weakened immune systems, such as those with HIV/AIDS or cancer, are more at risk of severe disease.
Symptoms of cyclosporiasis usually start within a week of exposure (eating or drinking contaminated food or water) and include:
While it is not yet fully understood how Cyclospora gets into food and water, individuals can prevent cyclosporiasis by not consuming food or water that may be contaminated with feces.
The US CDC advises people to take measures to prevent the foodborne illness such as:
Credit: iStock
Even as Uganda works to contain what is already the third-largest Ebola outbreak on record, centred in neighbouring Democratic Republic of Congo (DRC), the country is now facing the risk of the Marburg virus, another deadly filovirus disease.
Media reports have indicated a possible Marburg virus case in Uganda, although the country has not yet publicly declared an outbreak.
Uganda, however, formally reported a case of Marburg virus disease to the World Health Organization (WHO) on June 30, according to a STAT News report.
On June 29, the US Embassy in the Ugandan capital, Kampala, also issued a health alert regarding a possible case of Marburg virus disease in the country.
"The US Embassy is aware there are reports of a potential case of Marburg Virus Disease, a viral hemorrhagic fever, in western Uganda," the embassy said in its advisory.
The alert was issued as a Level 4 travel advisory, warning Americans not to travel to Uganda.
Also read: WHO Issues First Clinical Care Guidelines On Ebola And Marburg Disease
Uganda has extensive experience managing outbreaks of viral hemorrhagic fevers. The country last reported a Marburg virus outbreak in 2017, when there were four cases and three deaths.
However, responding to a potential Marburg outbreak while simultaneously battling Ebola could complicate public health efforts.
Both Ebola and Marburg virus disease are viral hemorrhagic fevers caused by closely related filoviruses. So far, Uganda has reported a total of 20 cases of the rare Bundibugyo species of Ebola, including two deaths. Of these, 15 cases were imported from the Democratic Republic of Congo.
Marburg virus disease belongs to the same virus family as Ebola and has a case fatality rate that has varied widely across outbreaks.
The virus is primarily carried by fruit bats and can spread to humans through prolonged exposure to infected bats or contaminated environments. Once a person is infected, the virus spreads from person to person through direct contact with the blood, bodily fluids, or contaminated surfaces and materials used by infected individuals.
Marburg virus disease typically begins with a sudden onset of high fever, severe headache and muscle pain. Other common symptoms include diarrhea, vomiting, abdominal pain and weakness.
In severe cases, patients may develop internal and external bleeding, organ failure and shock, which can be fatal.
There is currently no approved specific treatment or vaccine for Marburg virus disease. However, supportive care significantly improves survival, and several vaccines, antiviral drugs and immune therapies are under development, according to the World Health Organization (WHO).
According to the WHO, Marburg virus disease has killed between 24 per cent and 88 per cent of infected patients in previous outbreaks, depending on the virus strain and the quality of medical care available.
The virus was first identified in 1967 after simultaneous outbreaks occurred in Marburg and Frankfurt in Germany, and Belgrade in present-day Serbia. A total of 31 people were infected and seven died.
The outbreaks were traced to African green monkeys imported from Uganda for laboratory research. Fruit bats are now recognized as the natural reservoir of the virus, although other animals can also become infected.
Past outbreaks have been reported in countries including Angola, the Democratic Republic of Congo, Equatorial Guinea, Ghana, Kenya, South Africa, Uganda and Zimbabwe.
Outside Africa, only a handful of Marburg cases have been reported. Two fatal cases occurred in travelers who had visited bat-inhabited caves in Uganda—one in Europe and one in the United States.
Credit: AI-generated image
The Indian Society of Anaesthesiologists (ISA) has issued an urgent advisory asking anaesthesiologists and hospitals across the country to immediately stop administering Hyperbaric Bupivacaine manufactured by Themis for spinal anaesthesia until further notice.
Themis Hyperbaric Bupivacaine is commonly administered as a spinal anaesthesia. According to the ISA and the Anaesthesia Patient Safety Association (APSA), the anaesthesia resulted in several suspected adverse events.
These reports were significant enough to warrant an immediate nationwide safety alert, even though the exact cause and frequency of the adverse events have not been revealed yet.
However, according to Medical Dialogues, the Indian Society of Anaesthesiologists has suspected that the adverse incidents linked to Themis Hyperbaric Bupivacaine were reported at Apollo Hospitals and Yashoda Hospitals. They also said that Adverse Drug Reactions (ADRs) related to the drug have been reported, and an investigation is underway.
The associations also stressed that the advisory is strictly precautionary and does not imply that the drug is defective or that Themis is responsible for any negligence or unethical practices.
Apart from stopping the administration of Themis Hyperbaric Bupivacaine, the advisory has also asked hospitals and healthcare facilities to:
Dr Sherry Mathews, President of the Hyderabad Metro City Branch of the Indian Society of Anaesthesiologists, said, “This is a precautionary advisory issued in the interest of patient safety. Reports of serious adverse events have been received from multiple hospitals, and until the investigation is completed, we have advised doctors to stop using the product.”
Also read: Are Sea Squirts The Future Of Skin Cancer Treatment? New Study Says They Can Kill Melanoma Cells
A separate notice issued by the ISA's Hyderabad Metro City Branch directed consultants, resident doctors, anaesthesia technicians and operation theatre staff to immediately stop the use of Themis Bupivacaine for spinal anaesthesia.
It also said that no ampoules of the product should be used for neuraxial administration until an official clearance is issued. It added that any inadvertent use must be reported to the head of the department without fail.
The authorities are currently investigating these suspected adverse reactions, particularly their nature and association with the drug.
Themis Hyperbaric Bupivacaine, marketed under brand names like Bupicain Heavy, is manufactured by Themis Medicare Limited, a 53-year-old Indian pharmaceutical company.
It contains Bupivacaine hydrochloride 0.5% (5 mg/mL), a local anaesthetic. It also contains Dextrose, which makes the solution hyperbaric (heavier than cerebrospinal fluid), which helps anaesthesiologists control how the anaesthetic spreads through the spinal canal.
Hyperbaric bupivacaine is commonly used for:
Hyperbaric bupivacaine is widely trusted for spinal anaesthesia globally. Many pharmaceutical companies manufacture it. The concern raised by the Indian Society of Anaesthesiologists is not against the drug, but about one manufacturer's production.
© 2024 Bennett, Coleman & Company Limited